Aim Immunotech Stock Analysis

AIM
 Stock
  

USD 0.57  0.01  1.79%   

The big decline in price over the last few months for Aim Immunotech could raise concerns from stakeholders as the firm is trading at a share price of 0.57 on 20,626 in volume. The company executives failed to add value to investors and position the firm supply of money to exploit market volatility in September. However, diversifying your holdings with Aim Immunotech or similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.4. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Aim Immunotech partners.
Please continue to Trending Equities.
  
The Aim Immunotech stock analysis report makes it easy to digest most publicly released information about Aim Immunotech and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Aim Immunotech Stock analysis module also helps to analyze the Aim Immunotech price relationship with some important fundamental indicators such as market cap and management efficiency.

Aim Immunotech Stock Analysis Notes

About 14.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.45. Some equities with similar Price to Book (P/B) outperform the market in the long run. Aim Immunotech recorded a loss per share of 0.38. The entity had not issued any dividends in recent years. The firm had a split on the 11th of June 2019. AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida. Aim Immunotech operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 21 people. For more info on Aim Immunotech please contact Thomas Equels at 352 448 7797 or go to https://www.aimimmuno.com.

Aim Immunotech Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Aim Immunotech's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Aim Immunotech or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Aim Immunotech generated a negative expected return over the last 90 days
Aim Immunotech has some characteristics of a very speculative penny stock
Aim Immunotech has high historical volatility and very poor performance
Aim Immunotech is unlikely to experience financial distress in the next 2 years
The company reported the last year's revenue of 140 K. Reported Net Loss for the year was (19.37 M) with loss before taxes, overhead, and interest of (715 K).
Aim Immunotech has about 44.54 M in cash with (13.68 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.93, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Latest headline from www.businesswire.com: AIM ImmunoTech Board Files Definitive Proxy Statement and Sends Letter to Shareholders - Business Wire

Aim Immunotech Upcoming and Recent Events

Earnings reports are used by Aim Immunotech to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Aim Immunotech previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report30th of March 2022
Next Fiscal Quarter End31st of December 2021

Aim Immunotech SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Aim Immunotech prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Aim Immunotech investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Aim Immunotech specific information freely available to individual and institutional investors to make a timely investment decision.
9th of September 2022
Financial Statements and Exhibits. Regulation FD Disclosure
View
18th of July 2022
Financial Statements and Exhibits. Other Events
View
21st of June 2022
Financial Statements and Exhibits. Entry into a Material Definitive Agreement
View
17th of June 2022
Financial Statements and Exhibits. Entry into a Material Definitive Agreement
View
12th of April 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Entry into a Material Definitive Agreement
View
28th of March 2022
Financial Statements and Exhibits. Regulation FD Disclosure
View
16th of March 2022
Financial Statements and Exhibits. Other Events
View
7th of March 2022
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Entry into a Material Definitive Agreement
View

Aim Immunotech Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Aim Immunotech is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Aim Immunotech backward and forwards among themselves. Aim Immunotech's institutional investor refers to the entity that pools money to purchase Aim Immunotech's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Vanguard Group IncCommon SharesM1.6 M
Morgan StanleyCommon Shares1.6 M1.2 M
Blackrock IncCommon Shares816.7 K638 K
Geode Capital Management LlcCommon Shares382 K297 K
State Street CorpCommon Shares173.1 K135 K
Verition Fund Management LlcCommon Shares153 K119 K
Bridgeway Capital Management LlcCommon Shares151 K118 K
Note, although Aim Immunotech's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Aim Immunotech Market Capitalization

The company currently falls under 'Micro-Cap' category with total capitalization of 27.75 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Aim Immunotech's market, we take the total number of its shares issued and multiply it by Aim Immunotech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has Return on Asset of (16.05) % which means that on every $100 spent on asset, it lost $16.05. This is way below average. In the same way, it shows return on shareholders equity (ROE) of (31.17) %, meaning that it generated no profit with money invested by stockholders. Aim Immunotech management efficiency ratios could be used to measure how well aim immunotech manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 6th of October, Aim Immunotech shows the mean deviation of 2.59, and Risk Adjusted Performance of (0.16). Aim Immunotech technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to collect and analyze data for nineteen technical drivers for Aim Immunotech, which can be compared to its rivals. Please confirm Aim Immunotech information ratio, as well as the relationship between the value at risk and expected short fall to decide if Aim Immunotech is priced correctly, providing market reflects its regular price of 0.57 per share. As Aim Immunotech is a penny stock we also strongly suggest to validate its total risk alpha numbers.

Aim Immunotech Price Movement Analysis

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Mid-point over period is an average of Aim Immunotech highest and lowest values attained during the given period.
.

Aim Immunotech Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aim Immunotech insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aim Immunotech's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Aim Immunotech insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Stewart Appelrouth over three months ago via Macroaxis 
Acquisition by Stewart Appelrouth of 24500 shares of Aim Immunotech subject to Rule 16b-3
Peter Rodino over three months ago via Macroaxis 
Acquisition by Peter Rodino of 4902 shares of Aim Immunotech subject to Rule 16b-3
Dickey Robert Iv over six months ago via Macroaxis 
Aim Immunotech exotic insider transaction detected
Ellen Lintal over six months ago via Macroaxis 
Acquisition by Ellen Lintal of 50000 shares of Aim Immunotech subject to Rule 16b-3
Thomas Equels over six months ago via Macroaxis 
Acquisition by Thomas Equels of 21552 shares of Aim Immunotech subject to Rule 16b-3
Thomas Equels over six months ago via Macroaxis 
Acquisition by Thomas Equels of 11811 shares of Aim Immunotech subject to Rule 16b-3
Ellen Lintal over six months ago via Macroaxis 
Acquisition by Ellen Lintal of 100000 shares of Aim Immunotech subject to Rule 16b-3
Stewart Appelrouth over six months ago via Macroaxis 
Acquisition by Stewart Appelrouth of 19379 shares of Aim Immunotech subject to Rule 16b-3
Thomas Equels over six months ago via Macroaxis 
Acquisition by Thomas Equels of 11194 shares of Aim Immunotech subject to Rule 16b-3
Thomas Equels over six months ago via Macroaxis 
Acquisition by Thomas Equels of 10204 shares of Aim Immunotech subject to Rule 16b-3
Thomas Equels over six months ago via Macroaxis 
Acquisition by Thomas Equels of 9146 shares of Aim Immunotech subject to Rule 16b-3
Stewart Appelrouth over six months ago via Macroaxis 
Acquisition by Stewart Appelrouth of 50000 shares of Aim Immunotech subject to Rule 16b-3

Aim Immunotech Predictive Daily Indicators

Aim Immunotech intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Aim Immunotech stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Aim Immunotech Forecast Models

Aim Immunotech time-series forecasting models is one of many Aim Immunotech's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Aim Immunotech's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Aim Immunotech Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Aim Immunotech prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Aim Immunotech shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Aim Immunotech. By using and applying Aim Immunotech Stock analysis, traders can create a robust methodology for identifying Aim Immunotech entry and exit points for their positions.
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida. Aim Immunotech operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 21 people.

Current Aim Immunotech Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Aim Immunotech analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Aim Immunotech analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
5.0Strong Buy1Odds
Aim Immunotech current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Aim Immunotech analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Aim Immunotech stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Aim Immunotech, talking to its executives and customers, or listening to Aim Immunotech conference calls.
Aim Immunotech Analyst Advice Details

Aim Immunotech Stock Analysis Indicators

Aim Immunotech stock analysis indicators help investors evaluate how Aim Immunotech stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Aim Immunotech shares will generate the highest return on investment. By understating and applying Aim Immunotech stock analysis, traders can identify Aim Immunotech position entry and exit signals to maximize returns.
Quick Ratio60.29
Fifty Two Week Low0.5500
Revenue Growth17.90%
Shares Short Prior Month580.44k
Average Daily Volume Last 10 Day92.72k
Average Daily Volume In Three Month127.36k
Shares Percent Shares Out1.15%
Short Percent Of Float1.16%
Forward Price Earnings-1.66
Float Shares47.37M
Fifty Two Week High2.0200
Enterprise Value To Ebitda0.54
Fifty Day Average0.6900
Two Hundred Day Average0.8582
Enterprise Value To Revenue-61.49
Please continue to Trending Equities. You can also try Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Complementary Tools for analysis

When running Aim Immunotech price analysis, check to measure Aim Immunotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aim Immunotech is operating at the current time. Most of Aim Immunotech's value examination focuses on studying past and present price action to predict the probability of Aim Immunotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Aim Immunotech's price. Additionally, you may evaluate how the addition of Aim Immunotech to your portfolios can decrease your overall portfolio volatility.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Is Aim Immunotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aim Immunotech. If investors know Aim Immunotech will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aim Immunotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Aim Immunotech is measured differently than its book value, which is the value of Aim Immunotech that is recorded on the company's balance sheet. Investors also form their own opinion of Aim Immunotech's value that differs from its market value or its book value, called intrinsic value, which is Aim Immunotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aim Immunotech's market value can be influenced by many factors that don't directly affect Aim Immunotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aim Immunotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Aim Immunotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aim Immunotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.